Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma

European Journal of Immunology

Volumn 36, Issue 12, 2006, Pages 3371-3380

  Fujimura, Taku ^a   Nakagawa, Satoshi ^a   Ohtani, Tomoyuki ^a   Ito, Yumiko ^a   Aiba, Setsuya ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dendritic cell; Immunotherapy; Liposome; Melanoma; Poly IC

Indexed keywords

BETA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; LIPOSOME; PLACEBO; POLYINOSINIC POLYCYTIDYLIC ACID; TYROSINASE RELATED PROTEIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE; MELANOMA; NONHUMAN; PRIORITY JOURNAL; SPLEEN;

ANIMALS; ANTINEOPLASTIC AGENTS; CATIONS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELLS, CULTURED; DISEASE PROGRESSION; FEMALE; GROWTH INHIBITORS; HUMANS; INJECTIONS, INTRALESIONAL; INTERFERON INDUCERS; INTERFERON TYPE II; LIPOSOMES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; POLY I-C;

EID: 33845568917     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200636053     Document Type: Article

References (33)

1. Pimm M. V., Embleton, M. J. and Baldwin, R. W., Treatment of transplanted rat tumours with double-stranded RNA (BRL 5907). I. Influenced of systemic and local administration. Br. J. Cancer 1976. 33: 154-165.
2. Meier, H., Myers, D. D. and Huebner, R. J., Ineffectiveness of poly rI:rC on transplanted tumors induced by methylcholanthrene. Naturwissenschaften 1970. 57: 248-249.
3. Larson, V. M., Panteleakis, P. N. and Hilleman M. R., Influence of synthetic double-stranded ribonucleic acid (poly I:C) on SV40 viral oncogenesis and transplant tumor in hamsters. Proc. Soc. Exp. Biol. Med. 1970. 133: 14-19.
4. Parr, I., Wheeler, E. and Alexander, P., Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA. Br. J. Cancer 1973. 27: 370-389.
5. Heyes, J., Catherall, E. J. and Harnden, M. R., Antitumour evaluation of a ribonuclease resistant double-stranded RNA-polyquaternary ammonium complex (BRL 10739). Eur. J. Cancer 1974. 10: 431-435.
6. Cella, M., Salio, M., Sakakibara, Y., Langen, H., Julkuneu, I. and Lanzavecchia, A., Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J. Exp. Med. 1999. 189: 821-829.
7. Schulz, O., Diebold, S. S., Chen, M., Naslund, T. I., Nolte, M. A., Alexopoulou, I., Azuma, Y. T. et al., Toll-like receptor 3 promotes cross-priming to vints-infected cells. Nature 2005. 433: 887-892.
8. Le Bon, A., Etchart, N., Rossmann C., Ashton, M., Hou, S., Gewert, D., Borrow, P. and Tough, D. F., Cross-priming of CD8+ T cells stimulated by virus-induced type 1 interferon. Nat. Immunol. 2003. 4: 1009-1015.
9. Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi T., Miyagishi, M., Taira, K. et al., The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 2004. 5: 730-737.
10. Matsumoto, M., Funami K., Tanabe, M., Oshiumi, H., Shingai M., Seto, Y., Yamamoto, A. and Seya, T., Subcellular localization of Toll-like receptor 3 in human dendritic cells. J. Immunol. 2003. 171: 3154-3162.
11. Hirabayashi, K., Yano, J., Inoue, T., Yamaguchi, T., Tanigawara, K., Smyth, G. E., Ishiyama, K. et al., Inhibition of cancer cell growth by polyinosinic-polycytidylic acid/cationic liposome complex: a new biological activity. Cancer Res. 1999. 59: 4325-4333.
12. Uno, T., Hirabayashi, K., Murai, M., Yano, J. and Ozato, K, The role of IFN regulatory factor-3 in the cytotoxic activity of NS-9, a polyinosinic-polycytidylic acid/cationic liposome complex, against tumor cells. Mol. Cancer Ther. 2005. 4: 799-805.
13. Kunikata, N., Sano, K., Honda, M., Ishii, K., Matsunaga, J., Okuyama, R., Takahashi, K. et al., Peritumoral CpG oligodeoxynucleotide treatment inhibits tumor growth and metastasis of B16F10 melanoma cells. J. Invest. Dermatol. 2004. 123: 395-402.
14. Komenaka I., Hoerig, H. and Kaufman, H. L., Immunotherapy for melanoma. Clin. Dermatol. 2004. 22: 251-265.
15. Crittenden, M. R., Thanarajasingam, U., Vile, R. G. and Gough, M. J., Intratumoral immunotherapy: using the tumour against itself. Immunology 2005. 114: 11-22.
16. Crittenden, M., Gough, M., Harrington, K., Olivier, K., Thompson, J. and Vile, R. G., Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res. 2003. 63: 5505-5512.
17. Bonnotte, B., Crittenden, M., Larmonier, N., Gough, M. and Vile, R. G., MIP-3alpha transfection into a rodent tumor cell line increases intratumoral dendritic cell infiltration but enhances (facilitates) tumor growth and decreases immunogenicity. J. Immunol. 2004. 173: 4929-4935.
18. Fidler, I. J., Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res. 1978. 38: 2651-2660.
19. Nanni, P., Colombo, M. P., De Giovanni, C., Lollini, P. L., Nicoletti, G., Parmiani, G. and Prodi, G., Impaired H-2 expression in B16 melanoma variants. J. Immunogenet. 1983. 10: 361-370.
20. Celik, C., Lewis, D. A. and Goldrosen, M. H., Demonstration of immunogenicity with the poorly immunogenic B16 melanoma. Cancer Res. 1983. 43: 3507-3510.
21. Cohen, E. P. and Kim, T. S., Neoplastic cells that express low levels of MHC class I determinants escape host immunity. Semin. Cancer Biol. 1994. 5: 419-428.
22. Restifo, N. P., Kawakami, Y., Marincola, F., Shamamian P., Taggarse, A., Esquivel, F. and Rosenberg, S. A., Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. J. Immunother. 1993. 14: 182-190.
23. Kaklamanis, I., Leek, R., Koukourakis, M., Gatter, K. C. and Harris, A. L., Loss of transporter in antigen processing 1 wansport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res. 1995. 55: 5191-5194.
24. Bellone, M., Iezzi, G., Manfredi, A. A., Protti, M. P., Dellabona, P., Casorati, G. and Rugarli, C., In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. Eur. J. Immunol. 1994. 24: 2691-2698.
25. Bellone, M., Iezzi, G., Martin-Fontecha, A., Rivolta, L. Manfredi, A. A., Protti, M. P., Freschi, M. et al., Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells. J. Immunol. 1997. 158: 783-789.
26. Tanaka, K., Gorelik, E., Watanabe, M., Hozumi, N. and Jay, G., Rejection of B16 melanoma induced by expression of a transfected major istocompatibility complex class I gene. Mol. Cell. Biol. 1988. 8: 1857-1861.
27. + tumor-infiltrating lymphocytes. J. Immunol. 1994. 153: 1202-1215.
28. Wells, A. D., Rai, S. K., Salvato, M. S., Band, H. and Malkovsky, M., Restoration of MHC class I surface expression and endogenous antigen presentation by a molecular chaperone. Scand. J. Immunol. 1997. 45: 605-612.
29. Ailba, S. and Katz, S. I., Phenotypic and functional characteristics of in vivo-activated Langerhans cells. J. Immunol. 1990. 145: 2791-2796.
30. Tong, Y., Song, W. and Crystal, R. G., Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res. 2001. 61: 7530-7535.
31. Romani, N., Bruner, S., Brang, D., Kampgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G. et al., Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 1994. 180: 83-93.
32. Aiba, S., Terunuma, A., Manome, H. and Tagami, H., Dendritic cells differently respond to haptens and irritants by their production of cytokines and expression of co-stimulatory molecules. Eur. J. Immunol. 1997. 27: 3031-3038.
33. Becker, C., Pohla, H., Frankenberger, B., Schuler, T., Assenmacher, M., Schendel, D. J. and Blankengtein, T., Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med. 2001. 7: 1159-1162.